Nonetheless, there were no subsequent evaluations of the expression levels of genes tied to the HER2 signaling cascade, nor was there any genomic sequencing conducted on tumor tissue or circulating tumor DNA (ctDNA) to identify gene mutations or other genomic changes related to Trastuzumab resistance. This evidence concerns the gene ERBB2 and neoplasm.